Mar 9, 2023
Comments to FDA: Evaluating Drug Names for Similarities; Methods and Approaches
Docket Number:
2003N-0201
These comments are submitted in response to the public meeting of June 26 on evaluating drug names for similarities, which was co-sponsored by the FDA, PhRMA, and the Institute for Safe Medication Practices.
Issues: